Cargando…

Systemic Sclerosis Association with Malignancy

The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepri, Gemma, Catalano, Martina, Bellando-Randone, Silvia, Pillozzi, Serena, Giommoni, Elisa, Giorgione, Roberta, Botteri, Cristina, Matucci-Cerinic, Marco, Antonuzzo, Lorenzo, Guiducci, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674744/
https://www.ncbi.nlm.nih.gov/pubmed/36121543
http://dx.doi.org/10.1007/s12016-022-08930-4
_version_ 1784833217839235072
author Lepri, Gemma
Catalano, Martina
Bellando-Randone, Silvia
Pillozzi, Serena
Giommoni, Elisa
Giorgione, Roberta
Botteri, Cristina
Matucci-Cerinic, Marco
Antonuzzo, Lorenzo
Guiducci, Serena
author_facet Lepri, Gemma
Catalano, Martina
Bellando-Randone, Silvia
Pillozzi, Serena
Giommoni, Elisa
Giorgione, Roberta
Botteri, Cristina
Matucci-Cerinic, Marco
Antonuzzo, Lorenzo
Guiducci, Serena
author_sort Lepri, Gemma
collection PubMed
description The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc clinical and serological features identify patients at major risk to develop malignancy. In this context, among serological features, presence of anti-RNA polymerase III and anti-topoisomerase I autoantibodies seems to increase cancer frequency in SSc patients (particularly lung and breast cancers). Lung fibrosis and a long standing SSc pulmonary involvement have been largely proposed as lung cancer risk factors, and the exposure to cyclophosphamide and an upper gastrointestinal involvement have been traditionally linked to bladder and oesophagus cancers, respectively. Furthermore, immune checkpoint inhibitors used for cancer therapy can induce immune-related adverse events, which are more frequent and severe in patients with pre-existing autoimmune diseases such as SSc. The strong association between SSc and cancer occurrence steers clinicians to carefully survey SSc patients performing periodical malignancy screening. In the present review, the most relevant bilateral relationships between SSc and cancer will be addressed.
format Online
Article
Text
id pubmed-9674744
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96747442022-11-20 Systemic Sclerosis Association with Malignancy Lepri, Gemma Catalano, Martina Bellando-Randone, Silvia Pillozzi, Serena Giommoni, Elisa Giorgione, Roberta Botteri, Cristina Matucci-Cerinic, Marco Antonuzzo, Lorenzo Guiducci, Serena Clin Rev Allergy Immunol Article The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc clinical and serological features identify patients at major risk to develop malignancy. In this context, among serological features, presence of anti-RNA polymerase III and anti-topoisomerase I autoantibodies seems to increase cancer frequency in SSc patients (particularly lung and breast cancers). Lung fibrosis and a long standing SSc pulmonary involvement have been largely proposed as lung cancer risk factors, and the exposure to cyclophosphamide and an upper gastrointestinal involvement have been traditionally linked to bladder and oesophagus cancers, respectively. Furthermore, immune checkpoint inhibitors used for cancer therapy can induce immune-related adverse events, which are more frequent and severe in patients with pre-existing autoimmune diseases such as SSc. The strong association between SSc and cancer occurrence steers clinicians to carefully survey SSc patients performing periodical malignancy screening. In the present review, the most relevant bilateral relationships between SSc and cancer will be addressed. Springer US 2022-09-19 2022 /pmc/articles/PMC9674744/ /pubmed/36121543 http://dx.doi.org/10.1007/s12016-022-08930-4 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lepri, Gemma
Catalano, Martina
Bellando-Randone, Silvia
Pillozzi, Serena
Giommoni, Elisa
Giorgione, Roberta
Botteri, Cristina
Matucci-Cerinic, Marco
Antonuzzo, Lorenzo
Guiducci, Serena
Systemic Sclerosis Association with Malignancy
title Systemic Sclerosis Association with Malignancy
title_full Systemic Sclerosis Association with Malignancy
title_fullStr Systemic Sclerosis Association with Malignancy
title_full_unstemmed Systemic Sclerosis Association with Malignancy
title_short Systemic Sclerosis Association with Malignancy
title_sort systemic sclerosis association with malignancy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674744/
https://www.ncbi.nlm.nih.gov/pubmed/36121543
http://dx.doi.org/10.1007/s12016-022-08930-4
work_keys_str_mv AT leprigemma systemicsclerosisassociationwithmalignancy
AT catalanomartina systemicsclerosisassociationwithmalignancy
AT bellandorandonesilvia systemicsclerosisassociationwithmalignancy
AT pillozziserena systemicsclerosisassociationwithmalignancy
AT giommonielisa systemicsclerosisassociationwithmalignancy
AT giorgioneroberta systemicsclerosisassociationwithmalignancy
AT bottericristina systemicsclerosisassociationwithmalignancy
AT matuccicerinicmarco systemicsclerosisassociationwithmalignancy
AT antonuzzolorenzo systemicsclerosisassociationwithmalignancy
AT guiducciserena systemicsclerosisassociationwithmalignancy